U.S. markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.81
    +0.10 (+0.22%)
     
  • Gold

    1,806.40
    +0.90 (+0.05%)
     
  • Silver

    23.38
    +0.02 (+0.08%)
     
  • EUR/USD

    1.1923
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3386
    +0.0004 (+0.03%)
     
  • USD/JPY

    104.3930
    -0.0470 (-0.05%)
     
  • BTC-USD

    18,707.31
    +18,707.31 (+0.00%)
     
  • CMC Crypto 200

    368.46
    -2.05 (-0.55%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    0.00 (0.00%)
     

Recap: Epizyme Q2 Earnings

Benzinga Insights
·1 min read

Shares of Epizyme (NASDAQ:EPZM) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 9.43% over the past year to ($0.58), which beat the estimate of ($0.61).

Revenue of $2,467,000 decreased by 58.19% from the same period last year, which missed the estimate of $4,300,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

View more earnings on EPZM

Revenue guidance hasn't been issued by the company for now.

Price Action

Company's 52-week high was at $27.82

Company's 52-week low was at $9.73

Price action over last quarter: down 21.35%

Company Description

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.